Nicholas J Shubin1, Tam N Pham2, Kristan Lea Staudenmayer3, Brodie A Parent2, Qian Qiu4, Grant E O'Keefe5. 1. Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, Washington, USA. 2. Department of Surgery, University of Washington, Seattle, Washington, USA. 3. Department of Surgery, Stanford University, Stanford, California, USA. 4. Harborview Injury Prevention and Research Center, Department of Pediatrics, University of Washington, Seattle, Washington, USA. 5. Harborview Injury Prevention and Research Center, Department of Surgery, University of Washington, Seattle, Washington, USA.
Abstract
BACKGROUND: β-Adrenergic agents suppress inflammation and may play an important role in posttraumatic infections. Mechanisms may include inhibition of MAP kinase signaling. We sought to determine whether MKP-1 contributed to catecholamine suppression of innate immunity and also wanted to know whether early catecholamine treatment after traumatic injury increases the risk of later nosocomial infection. METHODS: We performed experiments using THP-1 cells and peripheral blood mononuclear cells from healthy individuals. We exposed cells to epinephrine and/or LPS and measured inflammatory gene transcription and MAP kinase activation. We inhibited MKP-1 activity to determine its role in catecholamine-induced immune suppression. Finally, we studied injured subjects to determine whether early catecholamine treatment was associated with nosocomial infection. RESULTS: Epinephrine increases MKP-1 transcripts and protein and decreases LPS-induced p38 and JNK phosphorylation and TNF-α gene transcription. RNAi inhibition of MKP-1 at least partially restores LPS-induced TNF-α gene expression (p = 0.024). In the clinical cohort, subjects treated with β-adrenergic agents had an increased risk of ventilator-associated pneumonia (aOR = 1.9; 95% CI = 1.3-2.6) and bacteremia (aOR = 1.5; 95% CI = 1.1-2.3). CONCLUSIONS: MKP-1 may have a role in catecholamine-induced suppression of innate immunity, and exogenous catecholamines might contribute to nosocomial infection risk.
BACKGROUND: β-Adrenergic agents suppress inflammation and may play an important role in posttraumatic infections. Mechanisms may include inhibition of MAP kinase signaling. We sought to determine whether MKP-1 contributed to catecholamine suppression of innate immunity and also wanted to know whether early catecholamine treatment after traumatic injury increases the risk of later nosocomial infection. METHODS: We performed experiments using THP-1 cells and peripheral blood mononuclear cells from healthy individuals. We exposed cells to epinephrine and/or LPS and measured inflammatory gene transcription and MAP kinase activation. We inhibited MKP-1 activity to determine its role in catecholamine-induced immune suppression. Finally, we studied injured subjects to determine whether early catecholamine treatment was associated with nosocomial infection. RESULTS:Epinephrine increases MKP-1 transcripts and protein and decreases LPS-induced p38 and JNK phosphorylation and TNF-α gene transcription. RNAi inhibition of MKP-1 at least partially restores LPS-induced TNF-α gene expression (p = 0.024). In the clinical cohort, subjects treated with β-adrenergic agents had an increased risk of ventilator-associated pneumonia (aOR = 1.9; 95% CI = 1.3-2.6) and bacteremia (aOR = 1.5; 95% CI = 1.1-2.3). CONCLUSIONS:MKP-1 may have a role in catecholamine-induced suppression of innate immunity, and exogenous catecholamines might contribute to nosocomial infection risk.
Authors: Juan C Mira; Lori F Gentile; Brittany J Mathias; Philip A Efron; Scott C Brakenridge; Alicia M Mohr; Frederick A Moore; Lyle L Moldawer Journal: Crit Care Med Date: 2017-02 Impact factor: 7.598
Authors: Joseph P Minei; Joseph Cuschieri; Jason Sperry; Ernest E Moore; Michael A West; Brian G Harbrecht; Grant E O'Keefe; Mitchell J Cohen; Lyle L Moldawer; Ronald G Tompkins; Ronald V Maier Journal: Crit Care Med Date: 2012-04 Impact factor: 7.598
Authors: Callie M Thompson; Tarah D Holden; Gail Rona; Balaji Laxmanan; R Anthony Black; Grant E OʼKeefe; Mark M Wurfel Journal: Ann Surg Date: 2014-01 Impact factor: 12.969
Authors: Jason L Sperry; Joseph P Minei; Heidi L Frankel; Micheal A West; Brian G Harbrecht; Ernest E Moore; Ronald V Maier; Ram Nirula Journal: J Trauma Date: 2008-01
Authors: Jeonghwan Lee; Jung Nam An; Jin Ho Hwang; Yong-Lim Kim; Shin-Wook Kang; Chul Woo Yang; Nam-Ho Kim; Yun Kyu Oh; Chun Soo Lim; Yon Su Kim; Jung Pyo Lee Journal: PLoS One Date: 2014-08-19 Impact factor: 3.240
Authors: David Rene Steike; Michael Hessler; Eberhard Korsching; Florian Lehmann; Christina Schmidt; Christian Ertmer; Jürgen Schnekenburger; Hans Theodor Eich; Björn Kemper; Burkhard Greve Journal: Cells Date: 2022-02-21 Impact factor: 6.600
Authors: Jelena Gotovina; Rodolfo Bianchini; Judit Fazekas-Singer; Ina Herrmann; Giulia Pellizzari; Ian D Haidl; Karin Hufnagl; Sophia N Karagiannis; Jean S Marshall; Erika Jensen-Jarolim Journal: Allergy Date: 2020-04-17 Impact factor: 13.146